312 results on '"Huot, Philippe"'
Search Results
2. Positive allosteric mGluR2 modulation with BINA alleviates dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
3. [3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain
4. Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
5. The mGluR2/3 orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
6. Activation of mGlu2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism
7. Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain
8. Pharmacokinetic profile of bitopertin, a selective GlyT1 inhibitor, in the rat
9. Distribution of [11C]-JNJ-42491293 in the marmoset brain: a positron emission tomography study
10. Evaluation of the effects of the mGlu2/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
11. Pharmacotherapy of Psychosis in Parkinson’s Disease
12. Anti-parkinsonian effect of the mGlu2 positive allosteric modulator LY-487,379 as monotherapy and adjunct to a low L-DOPA dose in the MPTP-lesioned marmoset
13. Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
14. Glycine and clozapine: potential relevance for the treatment of Parkinson's disease
15. Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset
16. Metabotropic glutamate receptors in Parkinson's disease
17. Cognition and serotonin in Parkinson's disease
18. Towards an Overdetermined Design for Informal High School Girls' Learning in Geospatial Technologies for Climate Change
19. Activation of mGlu2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism.
20. Anticonvulsant Agents for Treatment of Restless Legs Syndrome: A Case Report With Lamotrigine and a Review of the Literature.
21. [3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain.
22. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic
23. Metronidazole-induced encephalopathy in a patient with cirrhosis
24. Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
25. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset
26. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset
27. Pharmacokinetic profile of the selective [5-HT.sub.3] receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat
28. Tremor, Hallucinations, and Cognitive Decline
29. Forced into Retirement
30. Case of Parkinsonism That Never Had a Good Response to Levodopa
31. The MPTP-lesioned marmoset model of Parkinson’s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results
32. The mGlu2/3 antagonist LY-341,495 reverses the anti-dyskinetic and anti-psychotic effects of the mGlu2 activators LY-487,379 and LY-354,740 in the MPTP-lesioned marmoset
33. Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset
34. Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose
35. Pharmacotherapy of Psychosis in Parkinson’s Disease
36. Activation of mGlu2/3receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism
37. The 5‐HT2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset.
38. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat
39. Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset
40. The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset
41. 5-HT2A blockade for dyskinesia and psychosis in Parkinson’s disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review
42. Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat
43. Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset
44. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat
45. 5-HT1A agonists for levodopa-induced dyskinesia in Parkinson's disease
46. Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series
47. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson’s disease
48. Classic animal models of Parkinson’s disease: a historical perspective
49. Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
50. The mGluR2/3 orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.